| Annual Financials | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
Revenue  | 2,337 | 2,665 | 2,960 | 3,416 | 3,792 | 4,208 | 4,391 | 4,997 | 5,503 | 6,097 | 6,685 | 6,871 |
| Expenses | 1,977 | 2,250 | 2,505 | 2,774 | 3,074 | 3,337 | 3,389 | 3,832 | 4,143 | 4,396 | 4,715 | 4,841 |
| EBITDA | 360 | 415 | 455 | 642 | 718 | 871 | 1,002 | 1,165 | 1,360 | 1,701 | 1,970 | 2,030 |
| Operating Profit % | 13 % | 14 % | 14 % | 16 % | 16 % | 18 % | 21 % | 22 % | 23 % | 25 % | 26 % | 27 % |
| Depreciation | 15 | 14 | 16 | 16 | 17 | 60 | 58 | 66 | 70 | 71 | 72 | 73 |
| Interest | 1 | 3 | 2 | 4 | 2 | 9 | 18 | 19 | 16 | 12 | 11 | 15 |
| Profit Before Tax | 344 | 398 | 437 | 622 | 699 | 803 | 926 | 1,080 | 1,274 | 1,618 | 1,887 | 1,943 |
| Tax | 115 | 143 | 160 | 220 | 249 | 210 | 235 | 281 | 324 | 417 | 473 | 486 |
| Net Profit | 229 | 255 | 277 | 401 | 450 | 593 | 691 | 799 | 949 | 1,201 | 1,414 | 1,452 |
| EPS in ₹ | 107.75 | 120.12 | 130.19 | 188.81 | 211.93 | 279.04 | 325.04 | 375.87 | 446.80 | 565.28 | 665.62 | 683.40 |
Abbott
Abbott
29,930.00
-185.00
(-0.61%)
Key Fundamentals
Market Cap
63,599.20 Cr
EPS
665.62
PE Ratio
43.81
Dividend Yield
1.59 %
Industry
Healthcare 52 Week High
37,000.00
52 Week Low
25,325.00
PB Ratio
15.03
Debt to Equity
0.04
Sector
Pharmaceuticals Analyst Rating and Forecast
- By Refinitiv from6 analysts
Actual
Company News
View All News
Abbott India Limited completed a postal ballot through e-voting for the appointment of Mr. Darshan Gada as a Director. The e-voting period concluded on October 14, 2025, at 5:00 p.m. The resolution was approved by shareholders on October 14, 2025, as confirmed by the Scrutinizer's Report issued by Mr. Taizoon M. Khumri of Khumri Wagh Fatehi & Associates LLP. Mr. Gada's appointment as Director became effective August 18, 2025. The voting results are available on the company's website.
ABB India Shares Drop 35% in 12 Months Amid Operational Challenges and Valuation Correction
Sep 25, 2025
Sep 25, 2025ABB India shares have declined over 24% year-to-date and more than 35% over 12 months, underperforming peers Siemens and Cummins India. The stock currently trades at 57 times price-to-earnings ratio, representing a 23% discount to its five-year average of 74 times, while competitors trade at premiums to their historical averages. The decline stems from operational uncertainty, with sluggish customer decision-making delaying order conversions and JPMorgan expecting soft large-ticket business in the second half. Analysts believe the company has passed its margin peaks and revenues have been lower than anticipated due to macro factors. However, JPMorgan and Ambit Capital expect faster order conversion and stronger project pipeline ahead, with potential recovery in process industries capital expenditure supporting medium-term growth. Brokerages see 7% upside from current levels with 50% recommending a buy rating, though growth momentum is expected to remain range-bound.
Abbott India Seeks Shareholder Approval for Darshan Gada's Director Appointment via Postal BallotSep 11, 2025
Sep 11, 2025Abbott India Limited has issued a postal ballot notice seeking shareholder approval for the appointment of Mr. Darshan Gada as a Non-Executive Director. Gada was initially appointed as an Additional Director on August 18, 2025, based on the Nomination and Remuneration Committee's recommendation. The 43-year-old Chartered Accountant brings over 21 years of finance experience and currently serves as Regional Finance Director at Abbott Healthcare Private Limited. Remote e-voting will be conducted from September 15 to October 14, 2025, with results to be declared by October 16, 2025. The cut-off date for voting eligibility is September 5, 2025. KFin Technologies Limited will provide the e-voting facility, and the appointment requires ordinary resolution approval from shareholders.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,699.00 | #1 4,07,647.00 | 39.22 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 66.09 | |
6,593.00 | 1,75,023.40 | 75.84 | 9,712.00 | 18.67 | 2,191 | 26.74 | 69.16 | |
1,584.40 | 1,27,980.60 | 23.76 | 28,409.50 | 7.12 | 5,291 | 9.88 | 53.71 | |
3,581.40 | 1,21,210.80 | 60.49 | 11,539.40 | 6.99 | 1,911 | 19.91 | 52.12 | |
1,283.60 | 1,07,131.00 | #1 18.66 | 33,741.20 | 16.73 | 5,725 | -0.38 | 56.05 | |
1,004.90 | 1,01,116.50 | 21.48 | 23,511.00 | 18.55 | 4,615 | 2.60 | 52.84 | |
2,432.40 | 1,00,399.40 | 52.47 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 39.94 | |
1,931.20 | 88,208.40 | 23.70 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 45.02 | |
5,545.00 | 66,298.80 | 28.42 | 13,458.30 | 3.70 | 2,216 | 21.39 | 58.03 | |
29,930.00 | #10 63,599.20 | #7 43.81 | #10 6,684.70 | #7 9.64 | #10 1,414 | #5 11.55 | 43.69 |
Growth Rate
Revenue Growth
9.64 %
Net Income Growth
17.75 %
Cash Flow Change
-16.57 %
ROE
2.86 %
ROCE
-0.57 %
EBITDA Margin (Avg.)
5.63 %
Yearly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 1,374 | 1,617 | 2,066 | 2,416 | 2,941 | 3,547 | 3,840 | 4,224 | 4,556 | 5,194 | 5,917 |
| Fixed Assets | 96 | 109 | 110 | 81 | 105 | 270 | 251 | 271 | 237 | 225 | 336 |
| Current Assets | 1,226 | 1,451 | 1,893 | 2,266 | 2,761 | 3,205 | 3,519 | 3,853 | 3,025 | 3,246 | 4,742 |
| Capital Work in Progress | 4 | 3 | 6 | 2 | 1 | 2 | 1 | 1 | 4 | 10 | 18 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1,274 | 1,505 | 1,950 | 2,333 | 2,835 | 3,275 | 3,589 | 3,953 | 4,315 | 4,958 | 5,563 |
| Total Liabilities | 1,374 | 1,617 | 2,066 | 2,416 | 2,941 | 3,547 | 3,840 | 4,224 | 4,556 | 5,194 | 5,917 |
| Current Liabilities | 397 | 382 | 632 | 668 | 857 | 891 | 1,031 | 1,203 | 1,206 | 1,343 | 1,407 |
| Non Current Liabilities | 39 | 39 | 47 | 55 | 75 | 224 | 207 | 201 | 161 | 152 | 277 |
| Total Equity | 938 | 1,196 | 1,387 | 1,693 | 2,009 | 2,432 | 2,602 | 2,820 | 3,189 | 3,699 | 4,233 |
| Reserve & Surplus | 916 | 1,174 | 1,366 | 1,672 | 1,987 | 2,410 | 2,581 | 2,799 | 3,167 | 3,678 | 4,212 |
| Share Capital | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -30 | 91 | 62 | -165 | 99 | 8 | 73 | -86 | 107 | 52 | 269 |
| Investing Activities | -187 | -77 | -155 | -215 | -257 | -401 | -72 | -396 | -148 | -416 | 182 |
| Operating Activities | 215 | 249 | 307 | 153 | 499 | 626 | 727 | 948 | 893 | 1,213 | 1,012 |
| Financing Activities | -58 | -80 | -90 | -102 | -143 | -217 | -582 | -637 | -639 | -745 | -925 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.18 % | 0.18 % | 0.18 % | 0.16 % | 0.16 % | 0.16 % | 0.16 % | 0.16 % |
| DIIs | 4.60 % | 5.80 % | 4.30 % | 4.20 % | 4.96 % | 5.24 % | 7.73 % | 8.39 % | 8.62 % | 8.67 % | 8.71 % | 8.74 % | 8.91 % | 8.81 % | 8.99 % | 9.01 % | 8.92 % | 9.19 % | 9.11 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 16.15 % | 15.83 % | 15.60 % | 15.81 % | 15.15 % | 14.72 % | 14.60 % | 14.25 % | 14.07 % | 13.95 % | 13.89 % | 13.97 % | 13.80 % | 13.86 % | 13.65 % | 13.59 % | 13.66 % | 13.35 % | 13.43 % |
| Others | 4.26 % | 3.38 % | 5.11 % | 5.01 % | 4.91 % | 5.06 % | 2.68 % | 2.37 % | 2.32 % | 2.39 % | 2.42 % | 2.13 % | 2.12 % | 2.16 % | 2.21 % | 2.25 % | 2.28 % | 2.31 % | 2.31 % |
| No of Share Holders | 0 | 84,478 | 75,540 | 73,417 | 83,236 | 90,567 | 82,113 | 83,526 | 72,086 | 69,582 | 68,885 | 72,252 | 69,382 | 71,588 | 69,449 | 67,892 | 69,934 | 67,584 | 71,199 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 40 | 55 | 65 | 250 | 275 | 275 | 325 | 410 | 475 |
| Dividend Yield (%) | 0.00 | 0.73 | 0.75 | 0.42 | 1.67 | 1.55 | 1.26 | 1.2 | 1.33 | 1.59 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 21 Jul 2021 |  Dividend | ₹ 155.00 /share | 19 Jul 2021 | 16,224.75 | 17,427.95 |
| 21 Jul 2021 | Dividend | ₹ 120.00 /share | 19 Jul 2021 | 16,224.75 | 17,427.95 |
| 04 Aug 2022 | Dividend | ₹ 130.00 /share | 02 Aug 2022 | 16,529.20 | 20,621.45 |
| 04 Aug 2022 | Dividend | ₹ 145.00 /share | 02 Aug 2022 | 16,529.20 | 20,621.45 |
| 21 Jul 2023 | Dividend | ₹ 145.00 /share | 21 Jul 2023 | 20,970.55 | 23,665.10 |
| 21 Jul 2023 | Dividend | ₹ 180.00 /share | 21 Jul 2023 | 20,970.55 | 23,665.10 |
| 19 Jul 2024 | Dividend | ₹ 410.00 /share | 19 Jul 2024 | 25,945.60 | 28,795.65 |
| 08 Aug 2024 |  Annual General Meeting | NA | 08 Aug 2024 | 25,945.60 | 28,136.85 |
| 07 Nov 2024 |  Quarterly Result Announcement | NA | 07 Nov 2024 | 28,526.15 | 29,115.20 |
| 05 Feb 2025 | Quarterly Result Announcement | NA | 05 Feb 2025 | 26,518.15 | 26,142.55 |
| 15 May 2025 | Quarterly Result Announcement | NA | 15 May 2025 | 30,145.75 | 30,348.45 |
| 25 Jul 2025 | Dividend | ₹ 475.00 /share | 25 Jul 2025 | 30,348.45 | 34,580.00 |
| 12 Aug 2025 | Quarterly Result Announcement | NA | 12 Aug 2025 | 33,595.00 | 32,980.00 |
| 13 Aug 2025 | Annual General Meeting | NA | 13 Aug 2025 | 30,348.45 | 32,342.10 |
Announcements
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportOct 15, 2025
Oct 15, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 13, 2025
Oct 13, 2025Announcement under Regulation 30 (LODR)-Change in ManagementOct 08, 2025
Oct 08, 2025Announcement under Regulation 30 (LODR)-Change in ManagementSep 25, 2025
Sep 25, 2025Announcement under Regulation 30 (LODR)-Change in ManagementSep 24, 2025
Sep 24, 2025Closure of Trading WindowSep 24, 2025
Sep 24, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 12, 2025
Sep 12, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotSep 11, 2025
Sep 11, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 13, 2025
Aug 13, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 13, 2025
Aug 13, 2025Unaudited Financial Results For The Quarter Ended June 30 2025.Aug 12, 2025
Aug 12, 2025Board Meeting Outcome for Outcome Of Board MeetingAug 12, 2025
Aug 12, 2025Board Meeting Outcome for Outcome Of Board MeetingAug 12, 2025
Aug 12, 2025Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended On June 30 2025.Aug 04, 2025
Aug 04, 2025Disclosure Under Regulation 30Aug 01, 2025
Aug 01, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 29, 2025
Jul 29, 2025Communication Providing The Weblink Including Path Of Annual Report.Jul 18, 2025
Jul 18, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 18, 2025
Jul 18, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 18, 2025
Jul 18, 2025Notice Of The 81St Annual General Meeting Of The Company.Jul 18, 2025
Jul 18, 2025Reg. 34 (1) Annual Report.Jul 18, 2025
Jul 18, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 10, 2025
Jul 10, 2025Closure of Trading WindowJun 26, 2025
Jun 26, 2025Communication To Shareholders : Intimation About Tax Deduction At Source On Dividend.Jun 18, 2025
Jun 18, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 19, 2025
May 19, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 16, 2025
May 16, 2025Record Date For Entitlement Of DividendMay 15, 2025
May 15, 2025Annual General Meeting On August 13 2025May 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Dividend UpdatesMay 15, 2025
May 15, 2025Results For The Financial Year Ended March 31 2025May 15, 2025
May 15, 2025Board Meeting Outcome for Outcome Of Board MeetingMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 07, 2025
May 07, 2025Board Meeting Intimation for Intimation Under Regulation 29 (1) (A) And (E) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015.May 07, 2025
May 07, 2025Announcement Under Regulation 30.Apr 30, 2025
Apr 30, 2025Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 24, 2025
Apr 24, 2025Announcement under Regulation 30 (LODR)-Change in ManagementApr 18, 2025
Apr 18, 2025Announcement under Regulation 30 (LODR)-Change in ManagementApr 16, 2025
Apr 16, 2025Announcement under Regulation 30 (LODR)-Change in ManagementApr 16, 2025
Apr 16, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 10, 2025
Apr 10, 2025Announcement under Regulation 30 (LODR)-Change in ManagementApr 01, 2025
Apr 01, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMar 26, 2025
Mar 26, 2025Closure of Trading WindowMar 25, 2025
Mar 25, 2025Rumour verification - Regulation 30(11)Mar 06, 2025
Mar 06, 2025Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Feb 27, 2025
Feb 27, 2025Announcement under Regulation 30 (LODR)-Change in ManagementFeb 20, 2025
Feb 20, 2025Integrated Filing (Financial)Feb 06, 2025
Feb 06, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 06, 2025
Feb 06, 2025Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024Feb 05, 2025
Feb 05, 2025Board Meeting Outcome for Outcome Of Board MeetingFeb 05, 2025
Feb 05, 2025Mutual Fund Holdings
HSBC Midcap Fund Direct-Growth 
Tata India Pharma & Healthcare Fund Direct-Growth 
Bajaj Finserv Large and Mid Cap Fund Direct-Growth 
ICICI Prudential Children's Fund Direct-Growth 
Samco Flexi Cap Fund Direct - Growth 
UTI BSE Low Volatility Index Fund Direct - Growth 
Nippon India Multi Asset Allocation Fund Direct - Growth 
SBI Healthcare Opportunities Fund Direct Plan-Growth 
Bandhan Multi-Factor Fund Direct - Growth 
Union Large & Midcap Fund Direct - Growth 
LIC MF Large & Mid Cap Fund Direct-Growth 
Bank of India Mid & Small Cap Equity & Debt Fund Direct-Growth 
PGIM India Balanced Advantage Fund Direct - Growth 
Motilal Oswal BSE Low Volatility Index Fund Direct - Growth 
ITI Mid Cap Fund Direct - Growth 
360 ONE FlexiCap Fund Direct - Growth Technical Indicators
RSI(14)
Neutral 43.69
ATR(14)
Less Volatile 539.34
STOCH(9,6)
Neutral 52.60
STOCH RSI(14)
Overbought 80.08
MACD(12,26)
Bullish 100.52
ADX(14)
Strong Trend 25.57
UO(9)
Bearish 46.36
ROC(12)
Uptrend And Accelerating 0.35
WillR(14)
Neutral -63.96
About Abbott
Abbott India Ltd is a leading multinational pharmaceutical company in India. It operates an owned manufacturing facility in Goa and works with various independent contract manufacturers across the country. The company sells its products primarily within India through independent distributors. Abbott India provides pharmaceutical products and solutions across various therapeutic areas including Women's Health, Gastroenterology, Central Nervous System, Metabolics, Multi-Specialty, Vaccines, and Consumer Health. The company is structured into four divisions: Primary Care, Specialty Care-Methabolics and Urology, Specialty Care-Neuroscience, and Hospital Care. Abbott India manufactures and markets a wide range of products including Brufen, Prothiaden, Thyronorm, Leptos, Digene, Cremaffin, Influvac, and many others. The company has expanded its product portfolio through launches, acquisitions, and partnerships over the years. Abbott India is engaged in research and development, conducting clinical studies and publishing in medical journals. The company has also been recognized for innovation in the pharmaceutical industry.
Website
Chairperson NameMunir Shaikh
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
